Sionna Therapeutics Stock Forward View - Simple Exponential Smoothing
| SION Stock | 37.32 0.64 1.74% |
Momentum
Impartial
Oversold | Overbought |
EPS Estimate Next Quarter -0.52 | EPS Estimate Current Year -2.21 | EPS Estimate Next Year -2.58 | Wall Street Target Price 49.1111 | EPS Estimate Current Quarter -0.54 |
This section provides headline-driven context for Sionna Therapeutics Common alongside peer activity.
RSI Reading for Sionna
The Simple Exponential Smoothing forecasted value of Sionna Therapeutics Common on the next trading day is expected to be 37.30 with a mean absolute deviation of 1.28 and the sum of the absolute errors of 76.75.Sionna Therapeutics Hype to Price Pattern
The Sionna Therapeutics Common sentiment model analyzes how public information - from earnings calls to social media chatter - shapes investor behavior and, ultimately, Sionna Therapeutics' stock price.
Profiting from Sionna Therapeutics' sentiment mispricings requires combining sentiment signals with fundamental analysis. Sentiment alone is insufficient; it must be validated by the underlying business quality of Sionna Therapeutics.
The Simple Exponential Smoothing forecasted value of Sionna Therapeutics Common on the next trading day is expected to be 37.30 with a mean absolute deviation of 1.28 and the sum of the absolute errors of 76.75.Sionna Therapeutics after-hype prediction price | $ 37.32 |
The hype panel supports comparisons with forecasting models, technical signals, analyst consensus, and earnings.
Use Historical Fundamental Analysis of Sionna Therapeutics to cross-verify projections for Sionna Therapeutics. The view supplies historical context for the projection discussion.Sionna Therapeutics Additional Predictive Modules
Most predictive techniques to examine Sionna price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Sionna using various technical indicators. When you analyze Sionna charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Simple Exponential Smoothing Price Forecast For the 17th of March 2026
Given 90 days horizon, the Simple Exponential Smoothing forecasted value of Sionna Therapeutics Common on the next trading day is expected to be 37.30 with a mean absolute deviation of 1.28 , mean absolute percentage error of 3.39 , and the sum of the absolute errors of 76.75 .Please note that although there have been many attempts to predict Sionna Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Sionna Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Stock Forecast Pattern
| Backtest Sionna Therapeutics | Sionna Therapeutics Price Prediction | Research Analysis |
Forecasted Value
This next-day forecast for Sionna Therapeutics Common uses model performance to estimate practical downside and upside boundaries rather than a single point target alone. The projected forecast band currently runs from roughly 32.35 on the downside to about 42.26 on the upside.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of Sionna Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Sionna Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 117.4932 |
| Bias | Arithmetic mean of the errors | 0.1477 |
| MAD | Mean absolute deviation | 1.2791 |
| MAPE | Mean absolute percentage error | 0.0331 |
| SAE | Sum of the absolute errors | 76.7482 |
Investors who believe in mean reversion view Sionna Therapeutics' price extremes not as permanent states but as temporary dislocations that create opportunities for disciplined, contrarian capital allocation.
After-Hype Price Density Analysis
The shape of Sionna Therapeutics' price distribution after major news events tends to be skewed, with larger potential moves to the downside than to the upside for established companies like Sionna Therapeutics. This asymmetry is a key input for options pricing and risk management.
Next price density |
| Expected price to next headline |
Estimiated After-Hype Price Volatility
By studying Sionna Therapeutics' historical news reactions, we generate empirical estimates of the price boundaries that follow significant headlines. Sionna Therapeutics' after-hype downside and upside margins for the prediction period are 32.41 and 42.23, respectively. These estimates are most reliable when Sionna Therapeutics's news reaction patterns have been consistent over multiple events.
Current Value
This after-hype projection for Sionna Therapeutics Common uses a 3 months horizon to examine how price may behave after short-term sentiment effects dissipate. Sionna Therapeutics is Low at this time.
Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Sionna Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sionna Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Sionna Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.10 | 4.95 | 0.03 | 0.01 | 13 Events | 8 Events | In 13 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
37.32 | 37.32 | 0.00 |
|
Hype Timeline
Sionna Therapeutics is at this time traded for 37.32. The company has historical hype elasticity of -0.03, and average elasticity to hype of competition of -0.01. Sionna is estimated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is estimated to be very small, whereas the daily expected return is at this time at -0.1%. %. The volatility of related hype on Sionna Therapeutics is about 4159.66%, with the expected price after the next announcement by competition of 37.31. About 98.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.88. Sionna Therapeutics had not issued any dividends in recent years. Given the investment horizon of 90 days the next estimated press release will be in 13 days. Use Historical Fundamental Analysis of Sionna Therapeutics to cross-verify projections for Sionna Therapeutics. The view supplies historical context for the projection discussion.Related Hype Analysis
News about regulatory changes, technological disruptions, or macroeconomic shifts can affect Sionna Therapeutics' entire competitive landscape simultaneously. Monitoring peer reactions to such events helps investors anticipate Sionna Therapeutics's likely response.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| JANX | Janux Therapeutics | -0.11 | 7 per month | 0.00 | -0.07 | 4.02 | -4.43 | 22.72 | |
| ABCL | Abcellera Biologics | 0.16 | 5 per month | 4.24 | 0.02 | 8.41 | -6.22 | 28.69 | |
| MAZE | Maze Therapeutics Common | -2.72 | 7 per month | 2.88 | 0.11 | 5.95 | -4.37 | 17.46 | |
| BHVN | Biohaven Pharmaceutical Holding | -0.35 | 8 per month | 0.00 | 0.0008 | 7.92 | -5.70 | 31.69 | |
| CLDX | Celldex Therapeutics | -0.35 | 8 per month | 2.92 | 0.02 | 5.63 | -5.57 | 28.40 | |
| VERA | Vera Therapeutics | 1.11 | 9 per month | 0.00 | -0.03 | 6.23 | -4.32 | 12.83 | |
| XERS | Xeris Pharmaceuticals | -1.07 | 7 per month | 0.00 | -0.09 | 3.93 | -4.36 | 21.96 | |
| ZYME | Zymeworks Common Stock | -0.01 | 6 per month | 0.00 | -0.06 | 3.19 | -4.72 | 12.59 | |
| ARDX | Ardelyx | 1.15 | 15 per month | 3.78 | 0.03 | 10.57 | -5.51 | 35.05 | |
| IMNM | Immunome | 1.00 | 8 per month | 4.37 | 0.04 | 6.56 | -6.10 | 31.45 |
Other Forecasting Options for Sionna Therapeutics
Investors at all stages of experience who consider Sionna must develop an understanding of Sionna Therapeutics' price dynamics. The noise embedded in Sionna Stock price charts can create misleading signals and skew investment decisions.Sionna Therapeutics Related Equities
The following equities are related to Sionna Therapeutics within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Sionna Therapeutics against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Sionna Therapeutics Market Strength Events
Market strength indicators applied to Sionna Therapeutics stock give investors a structured view of the security's momentum relative to the overall market. Using these indicators, traders can refine their timing when entering or exiting positions in Sionna Therapeutics Common.
Sionna Therapeutics Risk Indicators
Evaluating Sionna Therapeutics' risk indicators is an important step in accurately forecasting its price and assessing the suitability of an investment. Understanding the risk profile of Sionna Therapeutics' allows investors to make more informed decisions about position sizing and risk.
| Mean Deviation | 3.18 | |||
| Standard Deviation | 4.78 | |||
| Variance | 22.87 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Sionna Therapeutics
A coverage review of Sionna Therapeutics Common helps investors see when the security is attracting above-average attention from contributors and market observers. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Contributor Headline
Latest Perspective From Macroaxis
Sionna Therapeutics Short Properties
A short-interest review of Sionna Therapeutics Common helps investors understand whether skepticism in the market is becoming more influential. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 40 M | |
| Cash And Short Term Investments | 235.9 M |
More Resources for Sionna Stock Analysis
A comprehensive view of Sionna Therapeutics starts with financial statements and ratio context. Ratio analysis helps investors evaluate Sionna Therapeutics Common Stock operating efficiency and financial trajectory. Highlighted below are reports that provide context for Sionna Therapeutics Common Stock:Use Historical Fundamental Analysis of Sionna Therapeutics to cross-verify projections for Sionna Therapeutics. The view supplies historical context for the projection discussion. Sionna Therapeutics currently shows ROE of -31.79%, market cap of 1.68 Billion. Investors get more value from Sionna Therapeutics analysis when it is combined with the construction and diversification tools listed below. A thorough Sionna Therapeutics review pairs this page with the quantitative and comparative resources listed below. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
The market value of Sionna Therapeutics is measured differently than book value, which reflects Sionna accounting equity. Sionna Therapeutics' market capitalization is 1.68 B. The 5.47 P/B ratio shows Sionna Therapeutics carries a substantial premium over its balance-sheet equity. Enterprise value stands at 1.45 B. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.
Note that Sionna Therapeutics' intrinsic value and market price are different measures derived from different inputs. For Sionna Therapeutics, key inputs include a P/B ratio of 5.47, and ROE of -31.79%. The actual Sionna Therapeutics transaction price is determined by real-time order flow on the exchange.